Opening
a New Front in the
War Against Cancer
Provectus Pharmaceuticals is developing advanced therapies designed to target and destroy the deadliest cancers – melanoma, liver & breast – while eliminating side effects. Our product pipeline includes:
Provectus' product pipeline also includes advanced therapies being developed to treat severe psoriasis and atopic dermatitis.
Further clinical trial information is available from the Melanoma Clinical Trial Update page, published literature, and at ClinicalTrials.gov.
Additionally, Provectus has developed groundbreaking biotechnologies to augment vaccine production and detect viruses (including an innovative “virus hunter” method); preparing to spinout the subsidiary that contains our novel over-the-counter skin care products; and seeks to license patented technologies for therapeutic and cosmetic medical devices.
For further information, read our detailed Research Reports.
Legal Notice ©2002-2013 Provectus Pharmaceuticals, Inc.
An article appearing in the May 2013 edition of Practical Dermatology
(10:5:31-32) summarizes PV-10 clinical development with input from Sanjiv S. Agarwala, MD. Recent non-clinical data supporting the use of
PV-10 with other chemotherapeutic agents and demonstrating that intralesional PV-10 induces a systemic immune response are also discussed.
Additionally, Dr. Agarwala discusses the suitability of IL PV-10 for use in a dermatology office setting.
* This article is reprinted with permission from Practical Dermatology.
An article appearing the May/June 2013 issue of Oncology News reports on the poster presentation recently made by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting showing the induction of a systemic immune response with intralesional PV-10.
Video of Dr. Robert H.I. Andtbacka's presentation at the HemOnc Today Melanoma and Cutaneous Malignancies Conference on March 22, 2013 entitled "Current Status of Injectible Therapy" is now available.
An article entitled "Back to Phase 1: Understanding Systemic Effects of PV-10" appearing in CancerWatch, Vol. 22 Feb. 2013, discusses the background and motivation for the Phase 1 study of the systemic antitumor effects of intralesional PV-10 treatment currently being conducted at the H. Lee Moffitt Cancer Center.
Slides from the presentation given by Craig Dees, Ph.D. at the 9th annual Noble Financial Equity Conference on January 22, 2013 in Hollywood, FL are now available.
In a Clinical Status update appearing January 14, 2013, BioCentury reports the initiation of a Phase I clinical trial to identify immune biomarkers in tumor tissue and peripheral blood after intralesional PV-10 injections into melanoma tumors.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) has received allowance from the United States Patent and Trademark Office (USPTO) of its patent application protecting the synthetic process used to produce the small molecule Rose Bengal. A notice of allowance is issued after the USPTO makes a determination that a patent can be granted.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) provides shareholders with an update on its corporate accomplishments, clinical progress and business development efforts during 2012, and shares well as insights on upcoming plans and milestones for 2013.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) announced details of a poster presentation on the induction of a systemic immune response with intralesional (IL) PV-10 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) presented data on PV-10 combination therapy today at the American Association for Cancer Research (AACR) Annual Meeting in Washington, DC.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) announced that a poster presentation detailing the induction of tumor specific immunity after intralesional PV-10 treatment was presented by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com) announces that mechanism data on the induction of tumor specific immunity after intralesional PV-10 treatment will be presented by researchers from Moffitt Cancer Center and the University of South Florida in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.
